Table 2. The comparison of CKD group and non-CKD group in each DOAC (a) Apixaban.
Data are presented as the mean ± standard deviation or n (%). Ccr, Creatinine clearance; CHADS2 score, Congestive Heart Failure, Hypertension, Age ≥ 75 Years, Diabetes Mellitus, Stroke History; CHA2DS2-VASc score, Congestive heart failure, Hypertension, Age≥75 years, Diabetes Mellitus, Previous Stroke/transient ischemic attack, Vascular disease, Age 65-74 years, Sex category; HASBLED score, Hypertension, Renal Disease and Liver Disease, Stroke History, Prior Major Bleeding or Predisposition to Bleeding, Age >65, Medication Usage Predisposing to Bleeding score
| CKD | Non-CKD | P value | |
|---|---|---|---|
| N | 388 (38.3) | 626 (61.7) | |
| Age (years) | 81.9±6.3 | 69.6±9.9 | <0.01 |
| Male (%) | 48 | 71 | <0.01 |
| Appropitate dose (%) | 79.8 | 75.2 | 0.38 |
| Body-weight (kg) | 50.6±9.9 | 63.0±11.4 | <0.01 |
| Ccr (ml/min) | 38.5±7.6 | 72.2±19.2 | <0.01 |
| CHADS2 score | 2.57±1.23 | 1.62±1.27 | <0.01 |
| CHA2DS2-VASc score | 4.26±1.41 | 2.77±1.62 | <0.01 |
| HAS-BLED score | 2.12±0.80 | 1.75±0.98 | 0.01 |
| Any cause death (per 100-patient years) | 5.5 | 1.9 | <0.01 |
| Major bleeding (per 100-patient years) | 3.9 | 2.3 | 0.21 |
| Stroke/systemic emboli (per 100-patient years) | 3.81.6 | 1.6 | 0.03 |